Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients

Journal of Hepatology

Volumn 30, Issue 3, 1999, Pages 536-550

  Locarnini, Stephen ^a   Birch, Chris ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CHRONIC DISEASE; COMORBIDITY; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

EID: 0032956306     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80118-4     Document Type: Review

References (127)

1. Richman DD. HIV therapeutics. Science. 272:1996;1886-1888.
2. Nicoll A, Locarnini S. Review: present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol. 12:1997;843-854.
3. Zoulim F, Trepo C. Review: drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol. 29:1998;151-168.
4. Bartholomeusz, A, Schinazi, RF and Locarnini, SA, Significance of mutations in the hepatitis B vírus polymerase selected by nucleoside analogues and implications for controlling chronic disease, Viral Hep Rev, in press.
5. Feinberg MB. Changing the natural history of HIV disease. Lancet. 348:1996;239-246.
6. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
8. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 242:1988;1171-1173.
9. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 2:1996;753-759.
10. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
11. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol. 13:1995;29-60.
12. Weissberg JI, Andres LL, Smith CI, Weick S, Nicholas Je, Garcia G, et al. Survival in chronic hepatitis B: an analysis of 397 patients. Ann Intern Med. 101:1984;613-616.
13. Hoofnagle JH. The treatment of chronic viral hepatitis. Drug Ther. 336:1997;347-356.
14. Milich DR, Jones JE, Hughes JL, Price J, Paney AK, McLachlan A. Function of the secreted hepatitis B e antigen to induce immunological tolerance in utero? Proc Natl Acad Sci USA. 87:1990;6599-6603.
15. Milich DR. Influence of T-helper cell subsets and cross regulation in hepatitis B virus infection. J Viral Hepat. 4:(suppl 2):1997;48-59.
16. Guidotti LG, Guilot S, Chisari FV. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumour necrosis factor-dependent and independent pathways. J Virol. 68:1994;1265-1270.
17. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
18. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
19. Kaufman D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 351:1998;723-724.
20. Lok ASF. Treament of chronic hepatitis B. J Viral Hepat. 1:1994;105-124.
21. Carithers RL. Effect of interferon on hepatitis B. Lancet. 351:1998;157.
22. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
23. 1, versus interferon alfa treatment in patients with hepatitis Be antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology. 24:1996;774-777.
24. 1 in patients with chronic hepatitis B: a randomised controlled trial. Hepatology. 27:1998;1383-1387.
25. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
26. Trepo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. [abstract] Hepatology. 24:1996;1881A.
27. Gilson R, Chopra K, Murray-Lyon I, Newell A, Nelson M, Tedder R, et al. A placebo-controlled phase I/II study of Adefovir Dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection. [abstract] Hepatology. 24:1996;281A.
28. Bloomer J, Chan R, Sherman M, Ingraham P, DeHertogh D, the -008 study group. A preliminary study of lobucavir for chronic hepatitis B. [abstract] Hepatology. 26:(4 Pt2):1997;428A.
29. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 69:1995;3350-3357.
30. Yokosuka O, Omata A, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology. 5:1985;728-734.
31. Dean J, Bowden S, Locarnini S. Reversion of duck hepatitis B virus DNA in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res. 27:1995;171-178.
32. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 71:1997;9392-9399.
33. Locarnini S, Civitico GM, Newbold JE. Hepatitis B: new approaches for antiviral chemotherapy. Antiviral Chem Chemother. 7:1996;53-64.
34. Civitico G, Locarnini S. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology. 203:1994;81-89.
35. Mason WS, Cullen J, Saputelli J, Wu T-T, Liu C, London WT, et al. Characterization of the antiviral effects of 2′-carbodeoxy-guanosine in ducks chronically infected with duck hepatitis B virus. Hepatology. 19:1994;398-411.
36. Luscombe C, Pedersen J, Uren E, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic viral DNA, RNA, and protein expression. Hepatology. 24:1996;766-773.
37. Lin E, Luscombe C, Wang Y, Shaw T, Locarnini S. The guanine nucleoside analogue penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 40:1996;413-418.
38. Lin E, Luscombe C, Colledge D, Wang YY, Locarnini SA. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 42:1998;2132-2137.
39. Averett DR, Mason WS. Evaluation of drugs for antiviral activity against hepatitis B virus. Viral Hepatitis Reviews. 1:1995;129-142.
40. Luciw P. Human immunodeficiency viruses and their replication. Fields BN, Knipe DM, Howley PM, . Fields Virology, 3rd ed. 1996;2703-2738 Lippincott-Raven, Philadelphia.
41. Ganem D. Hepadnaviridae: the viruses and their replication. Fields BN, Knipe DM, Howley PM, . Fields Virology, 3rd ed. 1996;2703-2738 Lippincott-Raven, Philadelphia.
42. Mansby LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 69:1995;5087-5094.
43. Locarnini S. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology. 27:1998;294-297.
44. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science. 271:1996;1582-1585.
45. Mellors JW, Riaaldo C, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
46. Nowak MA, Bouhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 93:1996;4398-4402.
47. Zeuzem S, deMan RA, Honkoop P, Roth WK, Scham SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol. 27:1997;431-436.
48. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171:1995;1411-1419.
49. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, MacCaffey R, et al. Development of HIV-1 resistance to (-) 2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 9:1995;351-357.
50. Najera I, Holguin A, Quinones-Mateu ME, Monoz-Fernandez MA, Najera R, Lopez-Galindez C, et al. Pol gene quasispecies of human immunodeficiency virus mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 69:1995;23-31.
51. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 27:1998;628-633.
52. 2-symmetric protease inhibitor. J Virol. 68:1994;2016-2020.
53. Holland JJ, De La Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microbiol Immunol. 176:1992;1-20.
54. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutie strategies. Ann Intern Med. 124:1996;984-994.
55. Furman P, Fyfe JA, St Clair M, Weinhold K, Ridcout JL, Freeman GA, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA. 83:1986;8333-8337.
56. Arnold E, Jacobo-Molina A, Nanni RG, Williams RL, Lu X, Ding S, et al. Structure of HIV-1 reverse transcriptase complexed with a double-stranded DNA template-primer: inplications for catalysis by and evolution of DNA polymerases. Int Antiviral News. 1:1992;3-4.
57. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol. 71:1997;1089-1096.
58. Condra J, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski W, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 70:1996;8270-8276.
59. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloar J, Casudevachari MB, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its gag substrate cleavage sites. J Virol. 71:1997;6662-6670.
60. Fischl MA, Richman DD, Grieco MH, Gottleib MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 317:1987;185-191.
61. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 70:1996;7894-7899.
62. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 243:1989;1731-1734.
63. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during drug therapy. J Virol. 68:1994;1660-1666.
64. Land S, McGavin C, Lucas R, Birch C. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. J Infect Dis. 166:1992;1139-1142.
65. Young SD, Britcher SF, Tran LO, Payne LS, Lumma C, Lyle TA, et al. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 39:1995;2602-2605.
66. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News. 4:1996;95-107.
67. Hertogs K, Mellors JW, Schel P, van Cauwenberghe A, Larder B, Kemp S, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. Abstract 395 (Session 52). 5th Conference on Retroviruses and Opportunistic Infections, Chicago. February 2-5, 1998.
68. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Qintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
69. Furman PA, Davis M, Liotta DC, Paff M, Frick JW, Nelson DJ, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1- (2-(hydroxymethyl)-1.3-oxathiolan-5-yl)cytosine. Antimicrob Agents Chemother. 36:1992;2686-2692.
70. Luscombe CA, Locarnini SA. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepatitis Reviews. 2:1996;1-35.
71. Shaw T, Locarnini S. Hepatic purine and pyrimidine metabolism: implications for the design of antiviral agents. Liver. 15:1995;169-184.
72. DeClercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Invervirology. 40:1997;295-303.
73. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:1996;25-36.
74. Cavanagh VJ, Guidotti LG, Chisari FV. Interleukin 12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 71:1997;3236-3243.
75. Dianzani F. The Interferon System. 1993;Health Sciences Press, London.
76. Scrrate SA, Schulof RS, Leondaridis L, Goldstcin AL, Sztein MB. Modulation of human natural killer cytotoxic activity, lymphokine production and interleukin 2 receptor expression by thymic hormones. J Immunol. 139:1987;2338-2343.
77. Gunther S, Meisel H, Reip A, Miska S, Kruger DH, Will H. Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology. 187:1992;271-279.
78. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV-RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
79. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 26:1997;1148-1153.
80. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson CC, Bunzendahl H, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
81. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of the reverse transcriptase. Proc Natl Acad Sci USA. 90:1993;5653-5656.
82. Schinazi RF, Lloyd RM Jr., Nguyen MH, Cannon DL, McMillan A, Ilksoy N, et al. Characterisation of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chermother. 37:1993;875-881.
83. Chiou HC, Kumura K, Hu A, Kerns KM, Coen DM. Penciclovir resistance mutations in the herpes simplex virus DNA polymerase gene. Antiviral Chem Chemother. 6:1995;281-288.
84. Ling R, Mutimer D, Ahmed M, Boxall E, Elias E, Dusheiko M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
85. Naoumov NV, Chokski S, Smith HM, Williams R. Emergence and characterization of lamivudine resistant hepatitis B virus variant. [abstract] Hepatology. 24:1996;282A.
86. de Man RA, Bartholomeusz A, Locarnini S, Niesters HGM, Zondervan PE. The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis acquired during lamivudine resistance. J Hepatol. 26:(Suppl 1):1997;79.
87. Lai CL, Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, et al. A 12 month course of lamivudine (100 mg od) therapy improves liver histology: results from a placebo controlled multicenter study in Asia. J Hepatol. 26:(Suppl 1):1997;79.
88. Honkoop P, Niesters HGM, deMan RAM, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol. 26:1997;1393-1395.
89. Tillman HL, Trautwein C, Bock T, Glowenka M, Kruger M, Boker K, et al. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. [abstract] Hepatology. 26:(4Pt2):1997;A1202.
90. Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology. 40:1997;337-342.
91. Locarnini SA, Aye TT, Shaw T, deMan R, Angus PW, McCaughan GW. The emergence of famciclovir resistance mutations in the hepatitis B virus polymerase during therapy following liver transplantation. [abstract] Hepatology. 26:(4 pt2):1997;A958.
92. Xiong X, Flores C, Gibbs C, Toole J. Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express Lamivudine resistance codons. [abstract] Hepatology. 26:(4Pt2):1997;A1211.
93. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters K, Tyrrell DLJ, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1998;1670-1677.
94. Haworth SJ, Christofalo B, Anderson RD, Dunkle LM. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immun Defic Syndr Hum Retrovirol. 17:1998;235-238.
95. Rolinski B, Bogner JR, Sadri I, Wintergerst U, Goebel FD. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immun Defic Syndr Hum Retrovirol. 15:1997;192-197.
96. van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 171:1995;1166-1171.
97. Burger DM, Kraayeveld CL, Meenhorst PL, Mulder JW, Hoetelmans RM, Koks CH, et al. Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS demential complex. Pharm World Sci. 17:1995;218-221.
98. Glynn SL, Yazdanian M. In vitro blood-brain permeability of nevirapine compared to other antiretroviral agents. J Pharm Sci. 87:1998;306-310.
99. Grootis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol. 3:1997;387-400.
100. Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology. 12:1991;364-366.
101. Luscombe C, Pedersen J, Bowden S, Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver. 14:1994;182-192.
102. Hadziyannis S. Hepatitis Be antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep Rev. 1:1995;7-36.
103. Lee J-Y, Colledge D, Locarnini S. Pathogenic effects of antiviral therapy in chronic hepatitis B virus infection. Schinazi RF, Sommadossi JP, Thomas HC, . Therapies for Viral Hepatitis. 1998;9-26 International Medical Press, London.
104. Nicoll A, Colledge DL, Toole JJ, Angus PW, Smallwood R, Locarnini S. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonyl-methoxyethyl)adenine (PMEA), an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother. 1998;. (in press).
105. Locarnini SA, Newbold JE., Chronic hepatitis B: the therapeutic challenge. J Antimicrob Chemother 39:559-65.
106. Corey L, Holmes KK. Therapy for human immunodeficiency virus infection: what have we learned? N Engl J Med. 335:1996;1142-1144.
107. Katzenstein DA, Hammer SM, Hughes MD. The relation of virologic and immunologic markers to clinical outcomes after nucleside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med. 335:1996;1091-1098.
108. Ho DD. Viral Counts count in HIV infection. Science. 272:1996;1124-1125.
109. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, et al. Line Probe Assay for rapid detection of drugselected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 41:1997;284-291.
110. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med. 126:1997;939-945.
111. Krajden M, Minor J, Zhao J, Comanor L. Multi-measurement method (MMM)-based assessment of commercial HBV DNA assays and the Roche Amplicor HBV Monitor™ test. [abstract] Hepatology. 26:(4Pt2):1997;317A.
112. Lau DT, Comanor L, Minor JM, Everhart JE, Wuestehube LJ, Hoofnagle JH. Statistical models for predicting a beneficial response to interferon alpha in patients with chronic hepatitis B. J Viral Hep. 5:1998;105-114.
113. Dean J, Bowden DS, Angus P, Locarnini S. Development of quantitative PCR to detect hepatitis B virus covalently closed circular DNA molecules in liver biopsy specimens. Hepatology. 28:(4Pt2):1998;. in press.
114. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1:1995;417-422.
115. McKenzie R, Fried MW, Sallie R, Conjeevaram H, DiBisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 333:1995;1099-1105.
116. Honkoop P, deMan RA, Scholte HR, Zondervan PE, Van Den Berg JWO, Rademekers LHPM, et al. Effect of lamikvudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology. 26:1997;211-215.
117. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 339:1998;61-68.
118. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 333:1995;450-451.
119. Condra JH, Emini EA. Preventing HIV-1 drug resistance. Science and Medicine. 4:1997;2-11.
120. Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, Barnes TG, et al. Acute AIDS retrovirus infection: definition of a clinical illness associated with seroconversion. Lancet. i:1985;537-540.
121. Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS. 5:1991;1-14.
122. Locarnini SA, Ayres A, Dean J, Angus P, Bartholomeusz A. Analysis of hepatitis B virus DNA isolated from liver and serum pre and post liver transplantion during the emergence of HBIG escape mutants. Hepatology. 28:(4, Pt2):1998;. in press.
123. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 26:197;216-225.
124. Fontana RJ, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology. 26:1997;234-237.
125. Kruger M, Baker KHW, Zeidler H, Manns MP. Treatment of hepatitis B-related polyartcritis nodosa with famciclovir and interferon alfa-2b. J Hepatol. 26:1997;935-939.
126. Heathcote J, Schalm SW, Cianciara J, Farrell G, Feinmann V, Shermann M, et al. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection. J Hepatol. 28:(Suppl 1):1998;43.
127. Lau GKK, Hou JL, Bartholomeusz A, Wang ZH, Sun J, Locarnini S. Mutations in"B domain" of polymerase gene during combination therapy of thymosin α-1 and famciclovir in immunotolerant Chinese chronic HBV carriers. Hepatology. 28:(4Pt2):1998;. In press.